ArticleCurrent issues in molecular biology2025
A New Method for Preparation of Decellularized Human Scaffolds for Facial Reconstruction.
Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Vascularized composite xenotransplantation: Where we have been and where we could go?Cell transplantationPooled it
- Decalcified and Decellularized Bone Conduits for Peripheral Nerve Regeneration: A Comparative In Vivo Study Using Rat Femur and Chicken Ulna Conduits.Brain and behavior · 2026Article
- Creating Engineered NAC Flaps Using in Vivo Revascularization: A Proof-Of-Concept Study.Stem cell reviews and reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Vascularized composite allotransplantation (VCA) has emerged as a robust alternative for addressing anatomically complex defects but requires a toxic lifelong immunosuppressive regimen. Tissue engineering offers the promise of creating recipient-specific alternative grafts using a decellularization and recellularization approach. In this article, we establish a reliable protocol for human face decellularization by immersion as a new tool in the development of engineered graft alternatives for reconstructive surgery. Three cadaveric face grafts were immersed in 1% sodium dodecyl sulfate for 216 h followed by 1% Triton X-100 for 48 h, without perfusion through the pedicle. We determined that decellularization was successfully accomplished for three facial specimens as confirmed by histological evaluation and quantification of DNA content. The extracellular components including collagen, glycosaminoglycans, elastin, and matrix-bound growth factors were preserved. Vascular architecture did not show significant differences between native and decellularized grafts as imaged by X-ray angiography. The mechanical strength of the grafts was not altered after decellularization. We also showed that the decellularized grafts were biocompatible in vitro and in vivo allowing cell engraftment. As a result, we have successfully developed a protocol to yield a clinical size decellularized graft suitable for generating a recellularized, potentially non-immunogenic graft for facial reconstruction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.